R&D Pipeline
Nektar Therapeutics has a targeted portfolio of novel therapeutics that target cytokine pathways and other mechanisms to selectively modulate the immune system and to advance the treatment of autoimmune disorders, chronic inflammatory conditions and cancer.
Nektar is also engaged in a series of co-development and commercialization collaborations with pharmaceutical industry leaders and emerging biotech companies.
Autoimmune Disorders
PEG-CSF Protein
Hematological Cancer
Large B-Cell Lymphoma
NKTR-255
+ Yescarta® or Breyanzi®
Phase 2/3
Solid Tumors
Maintenance Bladder Cancer
NKTR-255
+ Bavencio®
Phase 2
Solid Tumors
Advanced Non-small Cell Lung Cancer
NKTR-255
+ C-TIL051
Phase 1
Solid Tumors
Stage 2 Non-small Cell Lung Cancer Post Chemoradiation
NKTR-255
+ Imfinzi®
Phase 1/2
Hematological Cancer
Relapsed/Refractory Large B Cell Lymphoma
NKTR-255
+ Breyanzi®
Phase 1
NKTR-255
+ Breyanzi®
Hematological Cancer
B-Cell Acute Lymphoblastic Leukemia
NKTR-255
+ CD19/22.BB.z-CAR-T Cell
Phase 1
*Development candidate result of a research collaboration between Nektar and Biolojic
